Founded 2025 · Palm Beach, Florida
Breakthroughs that reach further.
Baxtra is building two things at once: a new generation of medicines, and the surgical technology that helps clinicians use them well. Four medicines in development. Three surgical platforms. $90 million invested in R&D since day one.
Who we are
A young company with an unusually wide brief.
Baxtra was founded in 2025 in West Palm Beach by a group of drug developers and surgical engineers who had spent their careers on opposite sides of the same hospital and rarely spoken to each other. The premise of the company is that those two disciplines belong in one building.
On the pharmaceutical side we are developing four investigational medicines across oncology, immunology, neuroscience and cardiometabolic disease. On the device side we are building surgical imaging, robotics and biomaterials that make procedures more precise and more repeatable.
We are privately held and pre-commercial in pharmaceuticals, working from a single campus in Palm Beach County, Florida.
What we are committed to
- Publish results from every trial we sponsor, positive or negative
- Design trials that enrol the populations the medicine will actually treat
- Set the access and pricing plan before a product reaches the market, not after
- Independent ethics review for every human study and device trial
- Human factors testing with practising surgeons on every device we ship
What we do
Two divisions, one research organisation
Baxtra Bio — medicines
Four investigational medicines built on targeted protein degradation, oral small molecules and genetic medicine. Every program starts from human evidence and carries a biomarker that tells us who will respond.
BX-101 · BX-204 · BX-308 · BX-412
See the pipelineBaxtra Surgical — technology
Intraoperative imaging, robotic soft-tissue instrumentation and bioresorbable biomaterials, developed with surgeons in our Palm Beach Gardens simulation lab.
Lumavue™ · Axion OR™ · SealWeave™
See the platformsTherapeutic areas
Where our medicines are aimed
Oncology
A targeted degrader against mutant KRAS G12D, designed to remove the oncoprotein rather than inhibit it.
Learn moreImmunology & Inflammation
An oral TL1A antagonist for Crohn’s disease, aimed at the fibrostenotic patients current biologics serve worst.
Learn moreNeuroscience
An antisense oligonucleotide in ALS, paired with a neurofilament biomarker strategy from first-in-human onward.
Learn moreCardiometabolic
An siRNA lowering lipoprotein(a), one of the most clearly genetically validated targets in cardiovascular medicine.
Learn moreWhy Palm Beach
We were told a research company had to be in Boston or the Bay Area. We think a single campus, a lower cost base and a team that actually lives near each other buys more science per dollar than a prestigious zip code — and Florida’s clinical infrastructure and device manufacturing base are badly underrated.
“We spent ninety million dollars in our first eighteen months. Every line of it is on the four medicines and the three devices — there is nothing else here to spend it on.”
From our founding research charter — Baxtra Research Labs, 2025
Newsroom
Latest from Baxtra
Pipeline
BX-101 doses first patient in Phase 1 solid tumour study
The dose-escalation study will evaluate our KRAS G12D degrader in patients with advanced pancreatic, colorectal and lung cancers at four US sites.
Read releaseRegulatory
Lumavue™ perfusion imaging system receives FDA 510(k) clearance
Baxtra’s first cleared product allows real-time assessment of tissue perfusion during bowel and reconstructive surgery.
Read releaseCompany
Baxtra passes $90 million invested in research and development
Eighteen months after founding, cumulative R&D spend reached $90 million across the pharmaceutical and surgical technology divisions.
Read releaseFor clinicians & surgeons
Device instructions for use, training, and medical information on our programs.
Clinician resourcesFor patients & caregivers
What our investigational medicines are, how trials work, and how to report a concern.
Patient resources